Skip to content

Flare Photometry in Uveitis Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01897935
Enrollment
100
Registered
2013-07-12
Start date
2013-06-30
Completion date
2014-04-30
Last updated
2014-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uveitis

Keywords

Uveitis

Brief summary

This is a cross sectional study of a novel non-invasive optical flare photometer (OFAM). Patients meeting the inclusion/exclusion criteria will receive a standard eye examination including a slit lamp examination to collect ocular flare data. In addition to the standard eye examination, subjects will receive flare measurements using the OFAM device.

Interventions

None listed

Sponsors

UW Medicine Eye Institute
CollaboratorUNKNOWN
ChromoLogic, LLC
Lead SponsorINDUSTRY

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Age greater than 18 years * Ability to understand and willingness to sign a written informed consent document. * To be eligible for the uveitis arm of the study subjects must have active anterior chamber uveitis in one or both eyes as determined by a physician * To be eligible for the non-inflammatory arm of the study the study subjects must have no ocular inflammation in either eye as determined by a physician.

Exclusion criteria

* Inability to give informed consent *

Design outcomes

Primary

MeasureTime frameDescription
Establish OFAM algorithms for quantitation of ocular flare3 monthsOFAM algorithms for quantitation of ocular flare will be established by comparing the output of the OFAM device to the flare measurements obtained during the standard slit lamp examination.

Secondary

MeasureTime frameDescription
Determine the impact that various potential confounders such as age and sex have on OFAM Measurements3 monthsOFAM data for various sub-groups (age and sex) will be compared in order to evaluate the degree to which each sub-group acts as a confounder for OFAM measurements.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026